David Dahan, PhD

Oncology Analyst @Datamonitor_HC

[sganguly @bmtdoc63]

I get asked this question quite often but cannot find an answer in one source, so I made this slide reviewing few papers and abstracts. please comment. @Abdallah81MD @End_myeloma @HenrychihangFu1 @adsouza_md @MyCancerHaven @NausheenAhmedMD @SurbhiSidanaMD

[Joseph Mikhael @jmikhaelmd]

Newly named Forimtamig (formerly RG6234) a bispecific targeting GPRC5D. Initially IV and now SC given q2wks. High rate of CRS (80%) but low grade and lower rate of infection. Response rate 64-71%. The list of bispecifics grows… #ASH22

[Raj Chakraborty @rajshekharucms]

Although I am super excited about teclistamab combinations in earlier lines of therapy, 6.25% fatal AEs 2/2 infection in Dara-Tec-Len is concerning. Need to develop new strategies to mitigate infection risk such that greater efficacy is not neutralized by high tox. #ASH22 #mmsm

[Rahul Banerjee, MD, FACP @RahulBanerjeeMD]

Excited to see orphan GPRC5D adopted by all of us at #ASH22!

@BerdejaJesus presented BMS-986393 (CAR-T, not bsAb). Great #MMsm ORRs, including prior BCMA. Just like MCARH109 (MSKCC NEJM study), less dysgeusia 👅 than we’ve seen with talq.

Excited to see further studies of both!

[Sue Sutter @PinkSheetSutter]

Another accelerated approval confirmatory trial failure: $GSK's Blenrep DREAMM-3 fails PFS primary endpoint for r/r multiple myeloma compared with PomDex; adverse survival trend (HR 1.14) w/ 37% of OS data mature. "Discussions with health authorities are currently ongoing."

[Maxime Chénard-Poirier @MaxCPoirier]

Impressive activity of CLDN18.2 targeted CAR-T in pretreated gastric cancer presented by Dr Qi. Quite nice to see CAR-T moving more and more in the solid tumor field. We need more of these! #ESMO2021 #gcsm

[Hope Rugo @hoperugo]

The data speaks for itself. Destiny breast 04: TDXd beats TDM1 in HER2+MBC. Longest PFS ever in this setting. OS trending better. Low ILD. A new SOC. @myESMO @OncoAlert #ESMO2021 @JavierCortesMD

[Hope Rugo @hoperugo]

A new treatment paradigm for metastatic HER2+ BC. Nice discussion of destiny breast 04 by Shanu Modi. ⁦@OncoAlert⁩ ⁦@myESMO⁩ #esmo2021

[Graham Collins @graham74GC]

POLARIX study meets primary endpoint. Press release: R-CHP+Pola had superior investigator assessed PFS compared with R-CHOP in 1st line high risk DLBCL.

A new standard of care in DLBCL? Has R-CHOP really been beaten? Can’t wait to see the data! #lymsm

https://t.co/xl3fCCu2Vd

[David Dahan, PhD @BMT_David1]

Article reports 2 cases of sequential anti-BCMA therapy. Discuss mechanisms of resistance including antigen escape, BCMA shedding, anti-drug antibodies, T-cell exhaustion, and the emergence of an immunosuppressive microenvironment https://t.co/XmdJ65KHyd

[David Dahan, PhD @BMT_David1]

#FDA Adcomm members vote 6-2 against maintaining approval of Keytruda monotherapy for 3L gastric cancer. Cite changing landscape with the recent approval of Opdivo + chemo for 1L patients however strongly recommend delaying removal of the Keytruda authorization for 6-12 months

[David Dahan, PhD @BMT_David1]

Nice summary of PI3K inhibitors approved for follicular lymphoma #AACR21

[David Dahan, PhD @BMT_David1]

Treatment of Chronic Lymphocytic Leukemia | NEJM https://t.co/KZB4ETzmjb

[David Dahan, PhD @BMT_David1]

File this one under incremental update. For Iomab arm, still no data for the key endpoints of the trial, durable CR and overall survival: Actinium Announces Positive Interim Results from Iomab-B Pivotal Phase 3 SIERRA Trial at 50% of Total Patient Enro... https://t.co/asRp2Sos7s

[Aaron Logan, MD, PhD, MPhil @hemedoc]

#BMTTandem18 Forman: engineered TCRs targeting AML WT1, early data look promising (no relapses when used prophylactically)

[Stephen Medlin @scmedlin]

EBV specific T cells target Wt-1 after Allo transplant as consolidation in AML. GREAT concept https://t.co/cLxIXkbfNH

[International Symposium Acute Leukemias - Munich @acuteleukemias]

Exciting second day of #ISAL2019 with lots of clinical data. We’re particularly excited about novel substances moving into 1st line for ‘fit’ patients, e.g. trials testing enasidenib / ivosidenib or idasanutilin (vs placebo) or gilteritinib (vs midostaurin) with 7+3... #leusm

[David Dahan, PhD @BMT_David1]

T Cell States Define Response, Resistance to Checkpoint ImmunoTx (ICI) in Melanoma: TCF7 could be used as a biomarker to identify patients who are likely to benefit from ICIs. CD39 and TIM3 were expressed at high levels on exhausted CD8+ T cells. https://t.co/tf2I03AAHA

[David Dahan, PhD @BMT_David1]

Research Update: Targeted Therapies Continue to Show Promise in CLL https://t.co/WSgrpTLjyf

[David Dahan, PhD @BMT_David1]

One year follow up of CD19 CAR-T patients for adverse events #ASH18